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Abstract
Background: Computerized Clinical Decision Support Systems (CCDSS) are information technology 
tools, designed to improve clinical decision-making. Telemedicine is a health care service delivery 
using videoconferencing, telephone or messaging technologies.
Objectives: Our project aimed at testing the effectiveness of a composite CCDSS and telemedicine 
approach designed to treat depression in primary care.
Methods: This cluster randomized trial involved four GP clinics located in Northern Italy. Two clinics 
were assigned to the experimental protocol, and two served as controls. The study compared the 
telemedicine group (TG), in which GPs had access to a CCDSS platform, with the control group (CG) 
in which GPs provided treatment as usual (TAU). Patients scoring ≥11 on Patient Heath Questionnaire 
and ≥26 on the Inventory of Depressive Symptomatology-Self-Report were eligible for participation. 
Patients were also administered the World Health Organization Quality of Life-BREF to assess quality 
of life and Medical Interview Satisfaction Scale 21 to assess satisfaction with the medical interview.
Results: Overall, 2810 patients were screened and 66 in the experimental group and 32 in the CG 
passed the screening stages and met inclusion criteria. The percentage of remitters at 6 months 
was significantly higher in the TG than in the CG group (24.1% versus 3.1%, χ 2 = 6.6, P = 0.01). This 
difference remained significant after adjusting for baseline confounders. Physical and psychological 
quality of life improved significantly from baseline in both groups. Patients reported, on average, 
good satisfaction with the medical interview.
Conclusions: Our study showed that a combined CCDSS and telemedicine approach may be more 
effective than the TAU offered by GPs to patients with depression.
Trial registration: The trial was registered on https://clinicaltrials.gov/ on 5 October 2012 with 
identifier: NCT01701791. The first participant was enrolled on 5 May 2014 and the study was 
completed on May 2016.
Key words:  Computerized Clinical Decision Support Systems, depression, patient–doctor relationship, primary care, quality of 
life, telemedicine.
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Treatment algorithms, guideline-based procedures and collab-
orative care systems based on electronic technology have been 
proposed and tested for optimizing the delivery of treatment for 
depression in primary care (1,2). However, the availability of 
the new technologies for the treatment of depression does not, 
per se, ensure good outcomes. The effectiveness of the proced-
ures adopted in fact depends not only on how the treatment itself 
(technology) is delivered but also on the quality of the interven-
tion content (adequacy and complexity).
Telemedicine is the simplest application of information tech-
nology for the treatment of medical diseases. It can be defined as 
a professional health care service delivery using information and 
communication technologies. It can support GPs in retrieving and 
exchanging valid information about diagnosis, treatment and pre-
vention of different diseases and health problems. One possibility for 
telemedicine is offered by text messaging (SMS). Simon et al. com-
pared antidepressant treatment in primary care with antidepressant 
treatment supported by SMS (3). They found that patients contacted 
with messages showed higher rates of antidepressant adherence, 
lower depression scores and greater satisfaction with treatment. 
Recently, Senanayake et al. reviewed nine telemedicine-based trials 
comparing text messaging interventions to a comparator group and 
found only marginal evidence supporting text messaging interven-
tions as an effective treatment modality for depression (4).
A more complex intervention is that offered by Computerized 
Clinical Decision Support Systems (CCDSS). CCDSS are infor-
mation systems designed to improve clinical decision-making. 
Characteristics of individual patients are recorded into a know-
ledge base, and software algorithms generate patient-specific recom-
mendations. Treatment algorithms are explicit treatment protocols 
that, based on recorded data, suggest specific therapeutic pathways; 
they are also decision-making tools assisting physicians in critical 
decision points throughout a given treatment course (1). The CCDSS 
have been used for a variety of clinical conditions, but these systems 
were rarely applied in the management of mental health problems in 
primary care (5).
Our project aimed to test the effectiveness of a treatment algo-
rithm designed to treat depression symptoms in GP versus treatment 
as usual (TAU). Our experimental procedure included some compo-
nents of CCDSS and others of telemedicine (SMS). The CCDSS plat-
form included an algorithm devised to guide the GPs’ choice about 
the best clinical approach, both in terms of antidepressant drugs 
and psychotherapeutic interventions, or referral for a specialist con-
sultation. The telemedicine component consisted of an SMS-based 
system aimed at reminding patients of medical prescriptions, sched-
uled appointments and regular exercise.
Methods
Study design
This cluster randomized trial involved four GP clinics located in two 
areas of Northern Italy (Brescia and Udine), for a total of 13 GPs. 
In each area, one clinic was randomly assigned to the experimental 
protocol, the other served as control. Patients were recruited in 
1 year and were followed up for 6 months.
In the two clinics randomized to the telemedicine group (TG), 
GPs had access to the experimental platform and were allowed to 
use all its features. However, GPs were not obliged to follow the 
guidance of such tool: indeed, the algorithm did not force them in 
any way—which would have been impractical and inappropriate on 
medical law grounds. In the two clinics randomized to the control 
group (CG), GPs provided TAU, which included all treatment op-
tions considered as appropriate by the GP.
Experimental platform for the TG group
The algorithm used in this project was an adapted version of 
the algorithm developed within the Texas Medication Algorithm 
Project (TMAP) (6), which was subsequently implemented with a 
computerized version (CCDSS), called CompTMAP (7). Our al-
gorithm was a computerized treatment system developed via ex-
pert consensus and used to treat depression (Fig. 1). It provided 
all prompts necessary to guide the GPs in the choice of the anti-
depressant and/or psychotherapeutic intervention and provided 
guidance about the need of a referral to a specialist service. The 
computer program also electronically recorded all patient infor-
mation, medication information, drug dosages, scheduled visits 
and progress notes, making them easily accessible thereby. The 
reminder program was driven by an automatic messaging system 
in which GPs recorded patient names, telephone numbers and 
next appointment days. The system sent automatically a text mes-
sage or a recorded voice mail to patients’ mobile phone twice 
a week to remind patients to comply with drug treatment and 
any other prescriptions. It also sent automatically two reminders, 
one on each of the two previous days before each scheduled GP 
appointment. A Patient Form specifically developed for this pro-
ject was used to survey patients’ socio-demographic, clinical- 
and treatment-related data and care pathway information. The 
Patient Form and the instruments listed below were used to assess 
all enrolled patients at baseline.
The CCDSS/telemedicine system had the following functions:
(i)   provide information to the GPs regarding patients’ severity of 
depression;
(ii)  support the GPs in the choice of the best treatment option;
(iii) increase patients’ treatment adherence by means of SMS;
(iv)  track GPs’ clinical decisions about patients’ depression;
(v)  provide suggestions about the management of possible side effects.
At the follow-up visits, the GP could evaluate the results of his/her 
clinical decisions. In particular, it was possible to check patient’s 
adherence to treatment and the side effects of the pharmacological 
treatment, if any.
The platform also included a section with additional materials 
of potential help to the GP: how to prevent relapses, possible psy-
chotherapeutic options and a table summarizing the properties of 
the most important antidepressant medications, including official 
dosage recommendations.
Key Messages
• Diagnostic algorithms may support GPs for treatment decisions.
• Information technology tools may be superior to usual care in treating depression.
• These tools may be useful for remote monitoring of drug treatment.
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Inclusion and exclusion criteria
Inclusion criteria were age between 18 and 65 and moderate depres-
sive symptomatology, defined by a score ≥11 on the Patient Health 
Questionnaire (PHQ)-9 and ≥26 on the Inventory of Depressive 
Symptoms Self-Report (IDS-SR).
Patients who met any of the following diagnostic criteria at base-
line were excluded: any antidepressant treatment prescription in the 
previous 3 months, current alcohol or substance dependence, history 
of bipolar disorder, pregnancy, being in treatment with antipsychotic 
medications or any clinical condition requiring inpatient or day-
hospital treatment.
Enrolment and monitoring procedures
A two-stage screening procedure was adopted to recruit study parti-
cipants. All consecutive patients visiting the four GP clinics on index 
days were administered the PHQ-9 (8,9). This instrument assesses 
the presence and the frequency of the nine symptom criteria for 
Diagnostic and Statistical Manual-IV (DSM-IV) major depression 
over the previous 2 weeks. It was specifically designed for use in GP 
to establish the possible presence of DSM-IV major depression.
Patients scoring ≥11 on the PHQ-9 were administered the 
30-item IDS-SR (10,11). This tool was used in several inpatient and 
outpatient psychiatric clinics and GP settings. Compared with the 
PHQ-9, it is more focused on physical symptoms that are the most 
common presentation of depression in GP. Overall scores on this in-
ventory range from 0 to 84 and can be categorized according to the 
severity of depressive symptoms (12).
Outcome measures
The primary outcome was clinical remission at 6 months, defined as 
an IDS-SR score ≤13. Secondary outcomes were quality of life and 
patients’ satisfaction with the medical interview.
To assess quality of life, patients were administered the World 
Health Organization Quality of Life-BREF (WHOQOL-BREF) at 
baseline and 6 months. This self-report instrument measures four do-
mains of quality of life: physical health, psychological, social relation-
ships and environment. de Girolamo et al. validated the Italian version 
in a sample of 379 people attending health care services and the tool 
proved to have good internal consistency (from 0.65 for social rela-
tionships to 0.80 for physical health), good test–retest reliability (from 
0.63 for environment to 0.88 for the psychological domain) and a sat-
isfactory concurrent validity with medical outcomes scale-short form-
36 for physical health and psychological domains (13).
The Medical Interview Satisfaction Scale (MISS-21) was admin-
istered only at 6 months. This instrument is designed to assess pa-
tients’ satisfaction with individual doctor–patient consultations and 
consists of four domains: Distress Relief, Communication Comfort, 
Rapport and Compliance Intent. It was validated in a UK general 
practice population and proved to have good acceptability and con-
struct validity (14).
Power analysis
We estimated that a sample of 180 patients (90 per arm) would be 
required to test a 20% difference in the percentage of remission be-
tween the TG and CG groups with a power of 80% and a level of 
significance α = 0.05. Moreover, to take into account the ‘clustered’ 
nature of the data, a correction to the original sample size was ap-
plied, assuming an intra-class correlation coefficient equal to 0.03. 
This leads to a total of 240 subjects to be recruited, that is, 15 pa-
tients for each of the 16 GPs.
Statistical analyses
Descriptive statistics were used to summarize all variables. Means 
and standard deviations were used for quantitative variables, ab-
solute frequency and percentage for categorical variables. The per-
centage of remitters and other categorical variables was compared 
between the experimental (TG) and the control (CG) groups using 
χ 2 test; and quantitative variables were compared between groups 
using t-test or Mann–Whitney test as appropriate.
Multiple logistic regression was used to compare the proportion 
of remission at 6 months between groups, adjusting for the poten-
tial confounding effect of age, gender, ongoing psychotherapy and 
Figure 1. Treatment algorithm. The red star refers to a further level of 
deepening.
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severity of depression at baseline. Repeated measures analysis of 
variance was used to compare the change of the quality of life do-
main scores from baseline to 6 months between groups. The signifi-
cance level was set at P < 0.05, and tests were two tailed. All analyses 
were conducted using IBM SPSS, version 25.0.
Results
Overall, 2810 patients were screened at the four GP clinics (Fig. 
2). The distribution of PHQ-9 scores stratified by age groups and 
gender is provided in Supplementary Table 1S). Overall, only 3.5% 
of patients passed the two steps of evaluation.
Ninety-eight (66 in the experimental units and 32 in the control 
units) patients agreed to fill out the IDS-SR and achieved a score 
greater than 26 at this second stage of evaluation. No significant dif-
ferences were found between the two groups on socio-demographic 
and clinical characteristics (Table 1). At baseline, 21/66 (31.8%) pa-
tients in the TG groups and 8/30 (27.6%) patients in the CG group 
started antidepressant treatment. The 21 TG patients continued their 
antidepressant treatment for 6 months and four more started treat-
ment during the study. Of the eight CG patients who started anti-
depressants at baseline, four continued their treatment until the end 
of the study and the other four discontinued it.
About one-fourth of patients (17/66, 25.8%) in the TG group 
received SMS (median = 73). The most frequent reminder was about 
doing regular exercise (median = 57).
The percentage of remitters (i.e. patients achieving an IDS-SR 
score ≤13 at 6  months) was significantly higher in the TG group 
than in the CG group (27.6% versus 9.4%, χ 2 = 4.1, P = 0.043). 
After adjusting for age, gender, any psychotherapy and IDS-SR score 
at baseline in a multiple logistic regression model, the difference be-
tween groups remained significant and the TG group had an odd 
ratio (OR) of remission more than four times as high as the CG 
group (OR = 4.6, 95% CI = 1.2–18.8; Table 2).
As to quality of life, no significant differences were found between 
the TG and the CG groups at baseline and 6 months. However, we found 
that WHOQOL physical and psychological scores increased significantly 
from baseline to 6 months, irrespective of the study group, while the so-
cial relationship score remained stable over time and the environment 
domain increased significantly only in the TG group (Table 3).
Concerning satisfaction with the medical interview, we found 
that MISS-21 scores were high in the subset of 64 patients who filled 
out the instrument at 6 months, pointing to good satisfaction for 
the doctor–patient relationship, high communication comfort, high 
compliance and distress relief. Domain scores did not differ signifi-
cantly between the TG and CG groups; however, communication 
comfort was higher among TG than CG patients (P = 0.054).
Table 1. Socio-demographic and clinical features of study participants 
(n = 98).
 
TG n = 66 CG n = 32 χ2 (P)
n (%) n (%)
Female gender 52 (78.8) 23 (71.9) 0.57 (0.45)
Education (≤8 years) 23 (34.8) 15 (46.9) 1.31 (0.25)
Employed 27 (40.9) 15 (46.9) 0.31 (0.06)
Single 18 (27.3) 6 (18.8) 0.85 (0.36)
Past history of depression 26 (39.4) 14 (43.8) 0.17 (0.68)
Past history of self-harm 5 (7.9) 3 (9.7) 0.08 (0.78)
Ongoing psychotherapy  
and/or counselling
11 (16.7) 1 (3.1) 3.68 (0.055)
 Mean (SD) Mean (SD) t-test (P)
Age 44.9 (12.0) 49.4 (11.9) 1.77 (0.09)
PHQ-9 15.4 (4.5) 15.2 (2.5) 0.34 (0.74)
IDS-SR 37.9 (8.7) 37.6 (8.6) 0.17 (0.87)
Data were collected in the framework of a cluster randomized trial carried 
out in 2014 in four GP units. 
SD, standard deviation.
Figure 2. CONSORT study diagram.




















To our knowledge, this is the first Italian study to test the effect-
iveness of CCDSS in patients with depression recruited in general 
practice. Our study shows that an intervention based on CCDSS 
and including elements of telemedicine is more effective than TAU 
in the management of PC patients with depression. The percentage 
of remitters at 6 months was significantly higher in the TG group 
(27.6%) than in the CG group (9.4%). This is an encouraging result, 
since most experiences in this latter field are not positive, similar to 
what happens in other fields of medicine (5). In a first study, Trivedi 
et al. had demonstrated the effectiveness of the non-computerized 
version of the TMAP algorithm (6). On the other hand, a subsequent 
randomized clinical trial in primary care showed no differences be-
tween CCDSS and controls (15). In a further trial, the use of com-
puterized guidelines led to a statistically but not clinically significant 
improvement compared to usual care after 6 weeks (16). So far, only 
Kurian et al. demonstrated the efficacy of a CCDSS-based treatment 
in a small sample of patients using a system similar to ours (17).
If we consider the process components that may have contrib-
uted to the greater efficacy of treatment in patients with TG, the 
literature provides some examples of variables associated with 
the effectiveness of treatments conducted with electronic or tele-
communication technology. In the study carried out by Simon 
et al., an improvement of depressive symptoms was present only 
if algorithm-based telephone recommendations to the GPs on 
drug strategies to adopt in case of poor efficacy or tolerability 
of therapies were provided (18). In the US multi-centre trial con-
ducted on 364 depressed primary care patients by Fortney et al., 
telemedicine-based collaborative care treatment proved to be more 
effective than practice-based collaborative care (19). Improved 
outcomes were associated with higher adherence to the care man-
ager protocol in the telemedicine-based model, which, however, 
did not lead to improvements in the quality of pharmacotherapy 
or telepsychotherapy. Quality of life in any case improved in the 
TG. Kurian et al. reported that the better outcomes of CCDSS pa-
tients were unrelated to quality of antidepressant treatment (e.g., 
adequacy of dosage, augmentation or switch strategies), while 
they were related to the number of physician visits (17).
In our study, improved outcomes were unrelated to age, gender 
and IDS-SR score at baseline. The proportion of patients starting anti-
depressant at baseline was also similar, around 30% in each group. 
However, if we take into account that other four patients in the experi-
mental group started an antidepressant during the trial and that half 
of the patient in the CG discontinued antidepressant treatment, the 
proportions of patients on antidepressants at 6 months were 37.9% 
in the experimental group and 13.3% in the CG. Treatment adherence 
is probably an important reason for the better outcome of patients 
receiving the CCDSS/telemedicine approach. Another reason is that 
it helped physicians understand for whom treatment was appropriate 
and facilitated shared decisions with the patients.
Table 2. OR of remission in the TG and CG groups, adjusted for 
age, gender, severity of depression and ongoing psychotherapy 
at baseline. 
B SE (B) OR 95% CI P
Group (TG versus CG) 1.529 0.716 4.613 1.134–18.763 0.033
Baseline IDS-SR −0.056 0.041 0.946 0.873–1.024 0.169
Age 0.019 0.025 1.019 0.969–1.071 0.465
Gender −0.625 0.664 1.869 0.509–6.865 0.346
Ongoing psychotherapy −0.456 0.904 0.634 0.108–3.726 0.614
Constant −1.407 2.300 0.245  0.982
Results of multiple logistic regression analysis (n = 98). Data were collected 
in the framework of a cluster randomized trial carried out in 2014 in four 
GP units. 
SE, standard error. 





CG (n = 32) TG (n = 66) CG (n = 24) TG (n = 45)
Mean SD Mean SD Mean SD Mean SD
Physical 12.3 2.6 12.2 2.1 13.4 2.4 13.6 2.8
Psychological 10.2 2.0 10.5 2.4 11.6 2.4 12.4 2.8
Social relationships 11.8 2.4 12.5 3.0 12.1 3.2 13.2 3.0
Environment 12.7 2.2 13.1 1.8 13.4 2.3 13.7 2.0
MISS-21 domain scores
 CG (n = 22) TG (n = 42) 
Mean SD Mean SD
Distress reliefb 31.6 9.4 31.9 8.3
Rapport^ 46.7 7.2 48.2 6.9
Compliance intent° 14.4 4.4 15.7 4.3
Communication comfort§ 19.7 4.6 21.9 4.8
Data were collected in the framework of a cluster randomized trial carried out in 2014 in four GP units. No significant differences on WHOQOL-BREF domains 
were found between the TG and CG groups at baseline and 6 months.
aWithin-group comparisons using paired samples t-test CG: physical: P = 0.037; psychological: P = 0.007; social relationships: P = 0.547; environment: 
P = 0.087; TG: physical P = 0.002; psychological: P < 0.001; social relationships: P = 0.125; environment: P < 0.05.
bBetween-group comparisons at 6 months using Mann–Whitney test: P = 0.788; ^P = 0.368; °P = 0.204; §P = 0.054
















E user on 09 D
ecem
ber 2020
Our study also suggests that the subjective experience of patients 
about the treatment received might be associated with the effective-
ness of the TG intervention. All patients reported a good satisfac-
tion with the GPs at 6 months, but communication satisfaction was 
higher, albeit not significantly, among TG patients. Further studies 
on larger samples are needed to explore satisfaction with the GPs in 
depressed patients using MISS-21.
A further comment is related to the fact that, in our study, tele-
medicine (i.e. the SMS) was used only to a limited extent, in line with 
the low algorithm adherence reported in the trial by Trivedi et al. (6). 
In our investigation, about one-fifth of patients refused to be con-
tacted with SMS and, in some cases, the GP themselves partially used 
the algorithm. Our study was conducted in areas where Continuing 
Medical Education programs among GPs are carried forward in a 
regular manner. This means that, in general, the GPs’ competence in 
the management of common mental disorders, such as depression, 
can be considered good. In this situation, the GP may be little mo-
tivated to add another tool to his/her professional armamentarium, 
especially because of time constraints and crowded clinics.
Limitations
The first limitation of our study is that the sample size was lower 
than anticipated. This was largely due to the low percentage of pa-
tients who passed the two-stage screening procedure: only 3.5% of 
patients met the inclusion criteria for the study. Even if this per-
centage can be considered fairly low, it is actually higher than that 
found in their large study by Fortney et  al.: from an initial pool 
of 19 285 patients screened for depression with the PHQ-9 (score 
threshold of 10), they found only 364 patients eligible and able to 
complete the baseline telephone interview (19). The main implica-
tion of the small sample is that the precision of the estimate of the 
proportion remitting is low, with a large confidence interval (CI).
The second limitation is that we relied only on self-reported 
measures. However, evidence from the literature suggests that a 
clinician-based assessment of depressive symptoms would not pro-
duce relevant differences from self-report measures, as shown by 
Trivedi et al., which obtained similar scores using the IDS clinician-
rated scale and the IDS self-report scale (6). We chose to use a PHQ-9 
score ≥11, although the most common cut-off for the PHQ-9 is 10. 
However, it was shown that cut-offs between 8 and 11 have similar 
sensitivity and specificity (20).
A third limitation might be that the four GP clinics are not rep-
resentative of the Italian practices. However, group practices are 
the most common form of association of GPs in Italy and they are 
similar to those of the other Italian GP practices, both in size and 
type of training. Thus, there are no reasons to believe that our results 
cannot be generalized to general practice in Italy. Lastly, the results 
may not be generalizable to many depressive patients in GP who 
have relatively mild illness with PHQ-9 score <11.
Conclusions
Our results indicate that a combined CCDSS and telemedicine ap-
proach to the treatment of depression may be superior to the usual 
care offered by GPs. These results can support the idea that informa-
tion technology tools might be useful when some obstacles hinder 
the delivery of optimal care, for example, when GPs’ knowledge of 
the best practice in mental health is low, when there are considerable 
geographical distances between GPs and their patients or under ex-
ceptional circumstances such, as the current COVID-19 outbreak.
Supplementary material
Supplementary material is available at Family Practice online.
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